Estrogen receptor explained

estrogen receptor 1 (ER-alpha)
Caption:A dimer of the ligand-binding region of ERα (PDB rendering based on).
Hgncid:3467
Symbol:ESR1
Altsymbols:ER-α, NR3A1
Entrezgene:2099
Omim:133430
Refseq:NM_000125
Uniprot:P03372
Pdb:1ERE
Chromosome:6
Arm:q
Band:24
Locussupplementarydata:-q27
estrogen receptor 2 (ER-beta)
Caption:A dimer of the ligand-binding region of ERβ (PDB rendering based on).
Width:200
Hgncid:3468
Symbol:ESR2
Altsymbols:ER-β, NR3A2
Entrezgene:2100
Omim:601663
Refseq:NM_001040275
Uniprot:Q92731
Pdb:1QKM
Chromosome:14
Arm:q
Band:21
Locussupplementarydata:-q22

Estrogen receptors (ERs) are a group of proteins found inside cells. They are receptors that are activated by the hormone estrogen (17β-estradiol).[1] Two classes of ER exist: nuclear estrogen receptors (ERα and ERβ), which are members of the nuclear receptor family of intracellular receptors, and membrane estrogen receptors (mERs) (GPER (GPR30), ER-X, and Gq-mER), which are mostly G protein-coupled receptors. This article refers to the former (ER).

Once activated by estrogen, the ER is able to translocate into the nucleus and bind to DNA to regulate the activity of different genes (i.e. it is a DNA-binding transcription factor). However, it also has additional functions independent of DNA binding.[2]

As hormone receptors for sex steroids (steroid hormone receptors), ERs, androgen receptors (ARs), and progesterone receptors (PRs) are important in sexual maturation and gestation.

Proteomics

There are two different forms of the estrogen receptor, usually referred to as α and β, each encoded by a separate gene (and, respectively). Hormone-activated estrogen receptors form dimers, and, since the two forms are coexpressed in many cell types, the receptors may form ERα (αα) or ERβ (ββ) homodimers or ERαβ (αβ) heterodimers.[3] Estrogen receptor alpha and beta show significant overall sequence homology, and both are composed of five domains designated A/B through F (listed from the N- to C-terminus; amino acid sequence numbers refer to human ER).

The N-terminal A/B domain is able to transactivate gene transcription in the absence of bound ligand (e.g., the estrogen hormone). While this region is able to activate gene transcription without ligand, this activation is weak and more selective compared to the activation provided by the E domain. The C domain, also known as the DNA-binding domain, binds to estrogen response elements in DNA. The D domain is a hinge region that connects the C and E domains. The E domain contains the ligand binding cavity as well as binding sites for coactivator and corepressor proteins. The E-domain in the presence of bound ligand is able to activate gene transcription. The C-terminal F domain function is not entirely clear and is variable in length.

Due to alternative RNA splicing, several ER isoforms are known to exist. At least three ERα and five ERβ isoforms have been identified. The ERβ isoforms receptor subtypes can transactivate transcription only when a heterodimer with the functional ERß1 receptor of 59 kDa is formed. The ERß3 receptor was detected at high levels in the testis. The two other ERα isoforms are 36 and 46kDa.[4] [5]

Only in fish, but not in humans, an ERγ receptor has been described.[6]

Genetics

In humans, the two forms of the estrogen receptor are encoded by different genes, and on the sixth and fourteenth chromosome (6q25.1 and 14q23.2), respectively.

Distribution

Both ERs are widely expressed in different tissue types, however there are some notable differences in their expression patterns:[7]

The ERs are regarded to be cytoplasmic receptors in their unliganded state, but visualization research has shown that only a small fraction of the ERs reside in the cytoplasm, with most ER constitutively in the nucleus.[11] The "ERα" primary transcript gives rise to several alternatively spliced variants of unknown function.[12]

Ligands

Agonists

Mixed (agonist and antagonist mode of action)

Antagonists

Affinities

Binding and functional selectivity

The ER's helix 12 domain plays a crucial role in determining interactions with coactivators and corepressors and, therefore, the respective agonist or antagonist effect of the ligand.[13] [14]

Different ligands may differ in their affinity for alpha and beta isoforms of the estrogen receptor:

Subtype selective estrogen receptor modulators preferentially bind to either the α- or the β-subtype of the receptor. In addition, the different estrogen receptor combinations may respond differently to various ligands, which may translate into tissue selective agonistic and antagonistic effects.[16] The ratio of α- to β- subtype concentration has been proposed to play a role in certain diseases.[17]

The concept of selective estrogen receptor modulators is based on the ability to promote ER interactions with different proteins such as transcriptional coactivator or corepressors. Furthermore, the ratio of coactivator to corepressor protein varies in different tissues.[18] As a consequence, the same ligand may be an agonist in some tissue (where coactivators predominate) while antagonistic in other tissues (where corepressors dominate). Tamoxifen, for example, is an antagonist in breast and is, therefore, used as a breast cancer treatment[19] but an ER agonist in bone (thereby preventing osteoporosis) and a partial agonist in the endometrium (increasing the risk of uterine cancer).

Signal transduction

Since estrogen is a steroidal hormone, it can pass through the phospholipid membranes of the cell, and receptors therefore do not need to be membrane-bound in order to bind with estrogen.

Genomic

In the absence of hormone, estrogen receptors are largely located in the cytosol. Hormone binding to the receptor triggers a number of events starting with migration of the receptor from the cytosol into the nucleus, dimerization of the receptor, and subsequent binding of the receptor dimer to specific sequences of DNA known as hormone response elements. The DNA/receptor complex then recruits other proteins that are responsible for the transcription of downstream DNA into mRNA and finally protein that results in a change in cell function. Estrogen receptors also occur within the cell nucleus, and both estrogen receptor subtypes have a DNA-binding domain and can function as transcription factors to regulate the production of proteins.

The receptor also interacts with activator protein 1 and Sp-1 to promote transcription, via several coactivators such as PELP-1.[2]

Tumor suppressor kinase LKB1 coactivates ERα in the cell nucleus through direct binding, in which it is recruited to the promoter of ERα-responsive genes. LKB1 catalytic activity enhances ERα transactivation compared with LKB1 catalytically deficient mutants.[20]

Direct acetylation of the estrogen receptor alpha at the lysine residues in hinge region by p300 regulates transactivation and hormone sensitivity.[21]

Non-genomic

Some estrogen receptors associate with the cell surface membrane and can be rapidly activated by exposure of cells to estrogen.[22] [23]

In addition, some ER may associate with cell membranes by attachment to caveolin-1 and form complexes with G proteins, striatin, receptor tyrosine kinases (e.g., EGFR and IGF-1), and non-receptor tyrosine kinases (e.g., Src).[2] [22] Through striatin, some of this membrane bound ER may lead to increased levels of Ca2+ and nitric oxide (NO).[24] Through the receptor tyrosine kinases, signals are sent to the nucleus through the mitogen-activated protein kinase (MAPK/ERK) pathway and phosphoinositide 3-kinase (Pl3K/AKT) pathway.[25] Glycogen synthase kinase-3 (GSK)-3β inhibits transcription by nuclear ER by inhibiting phosphorylation of serine 118 of nuclear ERα. Phosphorylation of GSK-3β removes its inhibitory effect, and this can be achieved by the PI3K/AKT pathway and the MAPK/ERK pathway, via rsk.

17β-Estradiol has been shown to activate the G protein-coupled receptor GPR30.[26] However the subcellular localization and role of this receptor are still object of controversy.[27]

Differences and malfunction

Cancer

Estrogen receptors are over-expressed in around 70% of breast cancer cases, referred to as "ER-positive", and can be demonstrated in such tissues using immunohistochemistry. Two hypotheses have been proposed to explain why this causes tumorigenesis, and the available evidence suggests that both mechanisms contribute:

The result of both processes is disruption of cell cycle, apoptosis and DNA repair, which increases the chance of tumour formation. ERα is certainly associated with more differentiated tumours, while evidence that ERβ is involved is controversial. Different versions of the ESR1 gene have been identified (with single-nucleotide polymorphisms) and are associated with different risks of developing breast cancer.[19]

Estrogen and the ERs have also been implicated in breast cancer, ovarian cancer, colon cancer, prostate cancer, and endometrial cancer. Advanced colon cancer is associated with a loss of ERβ, the predominant ER in colon tissue, and colon cancer is treated with ERβ-specific agonists.[28]

Endocrine therapy for breast cancer involves selective estrogen receptor modulators (SERMS), such as tamoxifen, which behave as ER antagonists in breast tissue, or aromatase inhibitors, such as anastrozole. ER status is used to determine sensitivity of breast cancer lesions to tamoxifen and aromatase inhibitors.[29] Another SERM, raloxifene, has been used as a preventive chemotherapy for women judged to have a high risk of developing breast cancer.[30] Another chemotherapeutic anti-estrogen, ICI 182,780 (Faslodex), which acts as a complete antagonist, also promotes degradation of the estrogen receptor.

However, de novo resistance to endocrine therapy undermines the efficacy of using competitive inhibitors like tamoxifen. Hormone deprivation through the use of aromatase inhibitors is also rendered futile.[31] Massively parallel genome sequencing has revealed the common presence of point mutations on ESR1 that are drivers for resistance, and promote the agonist conformation of ERα without the bound ligand. Such constitutive, estrogen-independent activity is driven by specific mutations, such as the D538G or Y537S/C/N mutations, in the ligand binding domain of ESR1 and promote cell proliferation and tumor progression without hormone stimulation.[32]

Menopause

The metabolic effects of estrogen in postmenopausal women has been linked to the genetic polymorphism of estrogen receptor beta (ER-β).[33]

Aging

Studies in female mice have shown that estrogen receptor-alpha declines in the pre-optic hypothalamus as they grow old. Female mice that were given a calorically restricted diet during the majority of their lives maintained higher levels of ERα in the pre-optic hypothalamus than their non-calorically restricted counterparts.[8]

Obesity

A dramatic demonstration of the importance of estrogens in the regulation of fat deposition comes from transgenic mice that were genetically engineered to lack a functional aromatase gene. These mice have very low levels of estrogen and are obese.[34] Obesity was also observed in estrogen deficient female mice lacking the follicle-stimulating hormone receptor.[35] The effect of low estrogen on increased obesity has been linked to estrogen receptor alpha.[36]

SERMs for other treatment purposes

SERMs are also being studied for the treatment of uterine fibroids[37] and endometriosis.[38]

Estrogen insensitivity syndrome

Estrogen insensitivity syndrome is a rare intersex condition with 5 reported cases, in which estrogen receptors do not function. The phenotype results in extensive masculinization. Unlike androgen insensitivity syndrome, EIS does not result in phenotype sex reversal. It is incredibly rare and is anologious to the AIS, and forms of adrenal hyperplasia. The reason why AIS is common and EIS is exceptionally rare is that XX AIS does not result in infertility, and therefore can be maternally inheirented, while EIS always results in infertility regardless of karyotype. A negative feedback loop between the endocrine system also occurs in EIS, in which the gonads produce markedly higher levels of estrogen for individuals with EIS (119–272 pg/mL XY and 750-3,500 pg/mL XX, see average levels) however no feminizing effects occur.[39] [40]

Discovery

Estrogen receptors were first identified by Elwood V. Jensen at the University of Chicago in 1958,[41] [42] for which Jensen was awarded the Lasker Award.[43] The gene for a second estrogen receptor (ERβ) was identified in 1996 by Kuiper et al. in rat prostate and ovary using degenerate ERalpha primers.[44]

See also

External links

Notes and References

  1. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA . International Union of Pharmacology. LXIV. Estrogen receptors . Pharmacological Reviews . 58 . 4 . 773–81 . Dec 2006 . 17132854 . 10.1124/pr.58.4.8 . 45996586 .
  2. Levin ER . Integration of the extranuclear and nuclear actions of estrogen . Molecular Endocrinology . 19 . 8 . 1951–9 . Aug 2005 . 15705661 . 1249516 . 10.1210/me.2004-0390 .
  3. Li X, Huang J, Yi P, Bambara RA, Hilf R, Muyan M . Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways . Molecular and Cellular Biology . 24 . 17 . 7681–94 . Sep 2004 . 15314175 . 506997 . 10.1128/MCB.24.17.7681-7694.2004 .
  4. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA . Mechanisms of estrogen action . Physiological Reviews . 81 . 4 . 1535–65 . Oct 2001 . 11581496 . 10.1152/physrev.2001.81.4.1535. 10223568 .
  5. Leung YK, Mak P, Hassan S, Ho SM . Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling . Proceedings of the National Academy of Sciences of the United States of America . 103 . 35 . 13162–7 . Aug 2006 . 16938840 . 1552044 . 10.1073/pnas.0605676103 . 2006PNAS..10313162L . free .
  6. Hawkins MB, Thornton JW, Crews D, Skipper JK, Dotte A, Thomas P . Identification of a third distinct estrogen receptor and reclassification of estrogen receptors in teleosts . Proceedings of the National Academy of Sciences of the United States of America . 97 . 20 . 10751–6 . Sep 2000 . 11005855 . 27095 . 10.1073/pnas.97.20.10751 . 2000PNAS...9710751H . free .
  7. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS . Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse . Endocrinology . 138 . 11 . 4613–21 . Nov 1997 . 9348186 . 10.1210/en.138.11.4613 . free .
  8. Yaghmaie F, Saeed O, Garan SA, Freitag W, Timiras PS, Sternberg H . Caloric restriction reduces cell loss and maintains estrogen receptor-alpha immunoreactivity in the pre-optic hypothalamus of female B6D2F1 mice . Neuro Endocrinology Letters . 26 . 3 . 197–203 . Jun 2005 . 15990721 .
  9. Hess RA . Estrogen in the adult male reproductive tract: a review . Reproductive Biology and Endocrinology . 1 . 52 . 52 . Jul 2003 . 12904263 . 179885 . 10.1186/1477-7827-1-52 . free .
  10. Babiker FA, De Windt LJ, van Eickels M, Grohe C, Meyer R, Doevendans PA . Estrogenic hormone action in the heart: regulatory network and function . Cardiovascular Research . 53 . 3 . 709–19 . Feb 2002 . 11861041 . 10.1016/S0008-6363(01)00526-0 . free .
  11. Htun H, Holth LT, Walker D, Davie JR, Hager GL . Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor . Molecular Biology of the Cell . 10 . 2 . 471–86 . Feb 1999 . 9950689 . 25181 . 10.1091/mbc.10.2.471 .
  12. Pfeffer U, Fecarotta E, Vidali G . Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells . Cancer Research . 55 . 10 . 2158–65 . May 1995 . 7743517 .
  13. Ascenzi P, Bocedi A, Marino M . Structure-function relationship of estrogen receptor alpha and beta: impact on human health . Molecular Aspects of Medicine . 27 . 4 . 299–402 . Aug 2006 . 16914190 . 10.1016/j.mam.2006.07.001 .
  14. Bourguet W, Germain P, Gronemeyer H . Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications . Trends in Pharmacological Sciences . 21 . 10 . 381–8 . Oct 2000 . 11050318 . 10.1016/S0165-6147(00)01548-0 .
  15. Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR . Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding . Endocrinology . 147 . 9 . 4132–50 . Sep 2006 . 16728493 . 10.1210/en.2006-0113 .
  16. Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N . Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release . Molecular and Cellular Endocrinology . 239 . 1–2 . 27–36 . Jul 2005 . 15950373 . 10.1016/j.mce.2005.04.008 . 42052008 .
  17. Bakas P, Liapis A, Vlahopoulos S, Giner M, Logotheti S, Creatsas G, Meligova AK, Alexis MN, Zoumpourlis V . Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness . Fertility and Sterility . 90 . 5 . 1878–85 . Nov 2008 . 18166184 . 10.1016/j.fertnstert.2007.09.019 . 10442/7330 . free .
  18. Shang Y, Brown M . Molecular determinants for the tissue specificity of SERMs . Science . 295 . 5564 . 2465–8 . Mar 2002 . 11923541 . 10.1126/science.1068537 . 2002Sci...295.2465S . 30634073 .
  19. Deroo BJ, Korach KS . Estrogen receptors and human disease . The Journal of Clinical Investigation . 116 . 3 . 561–70 . Mar 2006 . 16511588 . 2373424 . 10.1172/JCI27987 .
  20. Nath-Sain . Suchita . Marignani . Paola A. . 2009-04-15 . LKB1 catalytic activity contributes to estrogen receptor alpha signaling . Molecular Biology of the Cell . 20 . 11 . 2785–2795 . 10.1091/MBC.E08-11-1138 . 2688557 . 19369417.
  21. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SA, Lopez GN, Kushner PJ, Pestell RG . Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity . The Journal of Biological Chemistry . 276 . 21 . 18375–83 . May 2001 . 11279135 . 10.1074/jbc.M100800200 . free .
  22. Zivadinovic D, Gametchu B, Watson CS . Membrane estrogen receptor-alpha levels in MCF-7 breast cancer cells predict cAMP and proliferation responses . Breast Cancer Research . 7 . 1 . R101–12 . 2005 . 15642158 . 1064104 . 10.1186/bcr958 . free .
  23. Björnström L, Sjöberg M . Estrogen receptor-dependent activation of AP-1 via non-genomic signalling . Nuclear Receptor . 2 . 1 . 3 . Jun 2004 . 15196329 . 434532 . 10.1186/1478-1336-2-3 . free .
  24. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH . Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha . Proceedings of the National Academy of Sciences of the United States of America . 101 . 49 . 17126–31 . Dec 2004 . 15569929 . 534607 . 10.1073/pnas.0407492101 . 2004PNAS..10117126L . free .
  25. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P . Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase . Science . 270 . 5241 . 1491–4 . Dec 1995 . 7491495 . 10.1126/science.270.5241.1491 . 1995Sci...270.1491K . 4662264 .
  26. Prossnitz ER, Arterburn JB, Sklar LA . GPR30: A G protein-coupled receptor for estrogen . Molecular and Cellular Endocrinology . 265-266 . 138–42 . Feb 2007 . 17222505 . 1847610 . 10.1016/j.mce.2006.12.010 .
  27. Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, Langer G, Bader B, Prelle K, Nubbemeyer R, Fritzemeier KH . G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol . Endocrinology . 149 . 10 . 4846–56 . Oct 2008 . 18566127 . 10.1210/en.2008-0269 . free .
  28. Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith JC . Evaluation of an estrogen receptor-beta agonist in animal models of human disease . Endocrinology . 144 . 10 . 4241–9 . Oct 2003 . 14500559 . 10.1210/en.2003-0550 . free .
  29. Clemons M, Danson S, Howell A . Tamoxifen ("Nolvadex"): a review . Cancer Treatment Reviews . 28 . 4 . 165–80 . Aug 2002 . 12363457 . 10.1016/s0305-7372(02)00036-1 .
  30. Fabian CJ, Kimler BF . Selective estrogen-receptor modulators for primary prevention of breast cancer . Journal of Clinical Oncology . 23 . 8 . 1644–55 . Mar 2005 . 15755972 . 10.1200/JCO.2005.11.005 . free .
  31. Oesterreich S, Davidson NE . The search for ESR1 mutations in breast cancer . Nature Genetics . 45 . 12 . 1415–6 . Dec 2013 . 24270445 . 4934882 . 10.1038/ng.2831 .
  32. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, DeSchryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ . Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts . Cell Reports . 4 . 6 . 1116–30 . Sep 2013 . 24055055 . 3881975 . 10.1016/j.celrep.2013.08.022 .
  33. Darabi M, Ani M, Panjehpour M, Rabbani M, Movahedian A, Zarean E . Effect of estrogen receptor β A1730G polymorphism on ABCA1 gene expression response to postmenopausal hormone replacement therapy . Genetic Testing and Molecular Biomarkers . 15 . 1–2 . 11–5 . 2011 . 21117950 . 10.1089/gtmb.2010.0106 .
  34. Hewitt KN, Boon WC, Murata Y, Jones ME, Simpson ER . The aromatase knockout mouse presents with a sexually dimorphic disruption to cholesterol homeostasis . Endocrinology . 144 . 9 . 3895–903 . Sep 2003 . 12933663 . 10.1210/en.2003-0244 . free .
  35. Danilovich N, Babu PS, Xing W, Gerdes M, Krishnamurthy H, Sairam MR . Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice . Endocrinology . 141 . 11 . 4295–308 . Nov 2000 . 11089565 . 10.1210/endo.141.11.7765 . free .
  36. Ohlsson C, Hellberg N, Parini P, Vidal O, Bohlooly-Y M, Bohlooly M, Rudling M, Lindberg MK, Warner M, Angelin B, Gustafsson JA . Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice . Biochemical and Biophysical Research Communications . 278 . 3 . 640–5 . Nov 2000 . 11095962 . 10.1006/bbrc.2000.3827 .
  37. Lingxia X, Taixiang W, Xiaoyan C . Selective estrogen receptor modulators (SERMs) for uterine leiomyomas . The Cochrane Database of Systematic Reviews . 2 . CD005287 . April 2007 . 17443581 . 10.1002/14651858.cd005287.pub2 . Xie L .
  38. van Hoesel MH, Chen YL, Zheng A, Wan Q, Mourad SM . Selective oestrogen receptor modulators (SERMs) for endometriosis . The Cochrane Database of Systematic Reviews . 2021 . 5 . CD011169 . May 2021 . 33973648 . 8130989 . 10.1002/14651858.CD011169.pub2 . Cochrane Gynaecology and Fertility Group .
  39. Book: Thomas L. Lemke. David A. Williams. Foye's Principles of Medicinal Chemistry. 24 January 2012. Lippincott Williams & Wilkins. 978-1-60913-345-0. 1392–.
  40. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS . Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man . The New England Journal of Medicine . 331 . 16 . 1056–61 . October 1994 . 8090165 . 10.1056/NEJM199410203311604 . free .
  41. Jensen EV, Jordan VC . The estrogen receptor: a model for molecular medicine . Clinical Cancer Research . 9 . 6 . 1980–9 . Jun 2003 . 12796359 . abstract .
  42. Jensen E . A conversation with Elwood Jensen. Interview by David D. Moore . Annual Review of Physiology . 74 . 1–11 . 2011 . 21888507 . 10.1146/annurev-physiol-020911-153327 . free .
  43. David Bracey, 2004 "UC Scientist Wins 'American Nobel' Research Award." University of Cincinnati press release.
  44. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA . Cloning of a novel receptor expressed in rat prostate and ovary . Proceedings of the National Academy of Sciences of the United States of America . 93 . 12 . 5925–30 . Jun 1996 . 8650195 . 39164 . 10.1073/pnas.93.12.5925 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Estrogen receptor".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.